Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

The following resources are available to download to provide you with further information about DUPIXENT and support you in treating your patients with atopic dermatitis (AD)

DLQI Questionnaire

The DLQI questionnaire is a patient-reporting tool that consists of 10 questions measuring how their skin condition has affected their life over the last week. A high DLQI score indicates a greater impairment in quality of life.

POEM Questionnaire

The POEM questionnaire is a patient-reporting tool that consists of 7 questions designed to measure the severity of AD in your patients. A high POEM score indicates a greater degree of severity.
Further information about POEM.

Determining EASI

A useful tool explaining the step-by-step process of how to assess and score the severity of your patients’ AD. This will help you give them an accurate assessment and help with monitoring their AD.

Patient dosing calendar

A valuable tool for your moderate-to-severe AD patients prescribed DUPIXENT, to help monitor their treatment by keeping track of when they need to take their injections and any upcoming appointments they may have.

Dosing card

A useful tool detailing the recommended dosing for adults with moderate-to-severe AD and weight-based dosing for adolescents (12 years or older) with moderate-to-severe AD and children (6–11 years) with severe AD.

AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measure.

References

  1. DUPIXENT Summary of Product Characteristics. May 2021.